| Literature DB >> 29391587 |
Heinz Jungbluth1,2,3, Susan Treves4,5, Francesco Zorzato4,5, Anna Sarkozy6, Julien Ochala7, Caroline Sewry6, Rahul Phadke6, Mathias Gautel2, Francesco Muntoni6,8.
Abstract
The congenital myopathies are a group of early-onset, non-dystrophic neuromuscular conditions with characteristic muscle biopsy findings, variable severity and a stable or slowly progressive course. Pronounced weakness in axial and proximal muscle groups is a common feature, and involvement of extraocular, cardiorespiratory and/or distal muscles can implicate specific genetic defects. Central core disease (CCD), multi-minicore disease (MmD), centronuclear myopathy (CNM) and nemaline myopathy were among the first congenital myopathies to be reported, and they still represent the main diagnostic categories. However, these entities seem to belong to a much wider phenotypic spectrum. To date, congenital myopathies have been attributed to mutations in over 20 genes, which encode proteins implicated in skeletal muscle Ca2+ homeostasis, excitation-contraction coupling, thin-thick filament assembly and interactions, and other mechanisms. RYR1 mutations are the most frequent genetic cause, and CCD and MmD are the most common subgroups. Next-generation sequencing has vastly improved mutation detection and has enabled the identification of novel genetic backgrounds. At present, management of congenital myopathies is largely supportive, although new therapeutic approaches are reaching the clinical trial stage.Entities:
Mesh:
Year: 2018 PMID: 29391587 DOI: 10.1038/nrneurol.2017.191
Source DB: PubMed Journal: Nat Rev Neurol ISSN: 1759-4758 Impact factor: 42.937